Results 291 to 300 of about 3,330,143 (311)

Head and Neck Cancers [PDF]

, 2010
Head and neck cancers constitute approximately 10% of all cancers [1]. They are named according their location and subsite in the head or neck. Head and neck cancers are essentially seen in older patients (50–70 years), but they can also be seen in children, and they are more common in males than females.
Gokhan Ozyigit, Cuneyt Ebruli, Murat Beyzadeoglu   +2 more
openaire   +1 more source

Some of the next articles are maybe not open access.

Related searches:

An intergroup phase III comparison of standard radiation therapy and two schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer.

Journal of Clinical Oncology, 2003
PURPOSE The Head and Neck Intergroup conducted a phase III randomized trial to test the benefit of adding chemotherapy to radiation in patients with unresectable squamous cell head and neck cancer.
D. Adelstein, Yi Li, G. Adams, H. Wagner, J. Kish, J. Ensley, D. Schuller, A. Forastiere   +7 more
semanticscholar   +1 more source

The chemotherapy of head and neck cancer

Anti-Cancer Drugs, 1999
Studies of combination therapy [with agents such as cisplatin, 5-fluorouracil (5-FU) and methotrexate] have shown some improvements in response rate; however, no obvious survival advantage over monotherapy in the treatment of patients with metastatic or advanced locoregional cancer of the head and neck have been observed.
openaire   +6 more sources

Taxanes In Head and Neck Cancer

Future Oncology, 2005
Paclitaxel and docetaxel are cytotoxic agents that act on the microtubule system and cause cell death. They are active in patients with squamous cell carcinoma of the head and neck region. They can be combined with other cytotoxic agents and radiotherapy with acceptable toxicity.
Schrijvers, Dirk, Vermorken, Jan Baptist
openaire   +4 more sources

Alcohol‐related head and neck cancer: Summary of the literature

Head and Neck, 2019
Alcohol drinking is a risk factor for the development of head‐and‐neck malignancies, including oral, pharyngeal, and laryngeal cancers, and coupled with tobacco use, accounts for 75% of oral cancers.
A. Marziliano, S. Teckie, M. Diefenbach
semanticscholar   +1 more source

Immunotherapy for Head and Neck Cancer

Oral and Maxillofacial Surgery Clinics of North America, 2019
The immune system has a vital role in the development, establishment, and progression of head and neck squamous cell carcinoma (HNSCC). Immune evasion of cancer cells leads to progression of HNSCC. An understanding of this mechanism provides the basis for improved therapies and outcomes for patients.
Rom Leidner, Felix Sim, R.B. Bell
openaire   +5 more sources

Tobacco smoking, alcohol drinking, betel quid chewing, and the risk of head and neck cancer in an East Asian population

Head and Neck, 2018
The smoking prevalence among men in China is high, but the head and neck cancer incidence rates are low. This study's purpose was to investigate the impact of tobacco, betel quid, and alcohol on head and neck cancer risk in East Asia.
Y. Lee, Shuang Li, Yuji Chen, Qian Li, Chien-Jen Chen, W. Hsu, P. Lou, Cairong Zhu, Jian Pan, Hongbing Shen, Hongxia Ma, L. Cai, B. He, Yu Wang, Xiaoyan Zhou, Q. Ji, Baosen Zhou, Wei Wu, Jie Ma, P. Boffetta, Zuo‐Feng Zhang, M. Dai, M. Hashibe   +22 more
semanticscholar   +1 more source

The molecular landscape of head and neck cancer

Nature Reviews. Cancer, 2018
C. R. Leemans, P. Snijders, R. Brakenhoff   +2 more
semanticscholar   +1 more source

Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients.

Radiotherapy and Oncology, 2009
J. Pignon, A. le Maître, E. Maillard, J. Bourhis   +3 more
semanticscholar   +1 more source

Biomarkers for immunotherapy response in head and neck cancer.

Cancer Treatment Reviews, 2020
N. Gavrielatou, S. Doumas, P. Economopoulou, P. Foukas, A. Psyrri   +4 more
semanticscholar   +1 more source